ReviewHypertension research : official journal of the Japanese Society of Hypertension2023
Update in uric acid, hypertension, and cardiovascular diseases.
Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Association Between Serum Uric Acid and Atrial Fibrillation in Patients With Hypertension: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2025Pooled it
- GPR75 mediates hyperuricemia-induced endothelial inflammatory injury via a HOTAIR/miR-141-3p regulatory network.Molecular biology reports · 2026Article
- Lacticaseibacillus paracasei Jlus66 ameliorates hyperuricemia by inhibiting xanthine oxidase activity, modulating uric acid transporter proteins and the gut microbiota.Archives of microbiology · 2026Article
- Paper-based laser-written CoO-graphene biosensor for wireless sweat uric acid detection.Scientific reports · 2026Article
- Factors Associated With Hyperuricemia in Patients With Coronary Heart Disease.Reviews in cardiovascular medicine · 2026Article
- Long-term cardiovascular mortality risk of hyperuricemia and chronic kidney disease in a general Japanese population: NIPPON DATA90.Endocrine · 2026Article
- Comprehensive Review on Febuxostat for Hyperuricemia with Gout: Insights from Current Practice and Clinical Trials.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Article
- A Novel Risk Score Based on Lipid-Related Biomarkers for Acute Coronary Syndromes: A Multicenter Machine Learning Study.Reviews in cardiovascular medicine · 2026Article
- Predictive factors for atrial fibrillation recurrence after radiofrequency ablation: a multifactorial approach.BMC cardiovascular disorders · 2026Article
- Relative Fat Mass Associated with Hyperuricemia in Adults: A Cross-Sectional Study.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Association between exposure to proton pump inhibitors and hyperuricemia: risk prediction model establishment and nomogram construction.Frontiers in pharmacology · 2026Article
- Therapeutic potential of traditional Chinese medicine for hyperuricemia: mechanistic insights and clinical prospects.Frontiers in pharmacology · 2026Review
- Hyperuricemia-induced kidney injury: a narrative review of mechanisms and therapeutic advances.BMC nephrology · 2025Review
- Uncovering Nonlinear Predictors of Serum Biomarker Uric Acid Using Interpretable Machine Learning in Healthy Men.Biomedicines · 2025Article
- Relationship of the intensity of physical performance and sedentary time with uric acid in patients with type 2 diabetes.Journal of diabetes investigation · 2025Article
- Discovery of multi-target anti-gout agents from Eurycoma longifolia Jack through phenotypic screening and structural optimization.Nature communications · 2025Article
- The relationship between resting metabolic rate and hyperuricemia: is a higher metabolic rate better?Journal of health, population, and nutrition · 2025Article
- Uric acid and hypertension: insights from the joint symposium.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management.World journal of clinical cases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A direct relationship between serum uric acid levels and hypertension, cardiovascular, renal and metabolic diseases has been reported in many basic and epidemiological studies. Among these, high blood pression is one of the most common features associated with hyperuricemia. In this regard, several small-scale interventional studies have demonstrated a significant reduction in blood pressure in hypertensive or prehypertensive patients on uric acid-lowering drugs. These observation or intervention studies have led to affirm that there is a causal relationship between uric acid and hypertension. While the clinical association between uric acid and high blood pressure is notable, no clear conclusion has yet been reached as to whether lowering uric acid is beneficial to prevent cardiovascular and renal metabolic diseases. Recently, several prospective randomized controlled intervention trials using allopurinol and other uric acid-lowering drugs have been reported, and the results from these trials were almost negative, suggesting that the correlation between hyperuricemia and cardiovascular disease has no causality. However, it is important to note that in some of these recent studies there were high dropout rates and an important fraction of participants were not hyperuricemic. Therefore, we should carry caution in interpreting the results of these studies. This review article presents the results of recent clinical trials using uric acid-lowering drugs, focusing on hypertension and cardiovascular and renal metabolic diseases, and discusses the future of uric acid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.